Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis
- In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
- Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1